降胆固醇药物与糖尿病微血管并发症之间的因果关系:一种药物向的门德尔随机化研究
1Department of Endocrinology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Journal of diabetes research
|April 14, 2025
概括
降胆固醇药物,如HMGCR和PCSK9抑制剂,可能会增加糖尿病微血管并发症的风险. 然而,NPC1L1抑制剂显示出对糖尿病视网膜病变的潜在保护.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
背景情况:
- 降胆固醇治疗对糖尿病微血管并发症的影响尚不清楚.
- 研究药物标和这些并发症之间的因果关系对于开发新疗法至关重要.
研究的目的:
- 探索三种常见的降胆固醇药物标和糖尿病微血管并发症之间的因果关系.
- 评估HMGCR,PCSK9和NPC1L1抑制剂对糖尿病病,视网膜病和神经病的影响.
主要方法:
- 进行了一项针对药物的门德尔随机化 (MR) 研究.
- 使用与HMGCR,PCSK9和NPC1L1抑制剂相关的单核酸多态 (SNP).
- 核磁共振分析研究了对低密度脂蛋白胆固醇 (LDL-C) 介导的糖尿病并发症的影响.
主要成果:
- 抑制HMGCR显示糖尿病脏病,视网膜病和神经病的风险增加.
- PCSK9抑制剂与糖尿病脏病和神经病变的风险更高有关.
- NPC1L1抑制剂显示,糖尿病视网膜病变的发生率显著降低.
结论:
- HMGCR和PCSK9抑制剂可能会增加糖尿病微血管并发症的风险.
- NPC1L1抑制剂可以提供针对糖尿病视网膜病变的保护性益处.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
468
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
468
Targets for Drug Action: Overview
5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
Antihypertensive Drugs: Direct Renin Inhibitors
445
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
445
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
124
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
124
Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K
Principles of Drug Action
5.6K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
5.6K


